Business
Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilization and motion preservation s
About this update from Xtant Medical Holdings, Inc.
[{"type":"text","content":"Transaction expected to facilitate enhanced focus on Xtant's core businesses ","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilization and motion preservation systems for the treatment of spine and back pain. Companion Spine is a portfolio company of Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space.","length":743,"tagName":"p"},{"type":"image","alt":"Xtant Medical Logo","displaySize":"","headline":null,"caption":"Xtant Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/46c9cfa2f4f133a34a9e506f23e2f7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ylwl3kRtmzHnxrBIw2IQ3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/46c9cfa2f4f133a34a9e506f23e2f7a1","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2725938/XTNT_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The proceeds of the transaction total $19.2 million, consisting of $11 million in cash at closing and $8.2 million in short-term seller financing. Xtant expects to use the proceeds to reduce long-term debt and provide additional cash liquidity. The transaction is expected to close in the third quarter of 2025. As part of the transaction, Companion Spine expects to transition certain members of the Xtant U.S. and international commercial organizations, who will continue to support these products. ","length":513,"tagName":"p"},{"type":"text","content":"Sean Browne, President and CEO of Xtant Medical, stated, &quo...